GON(SZ:002768)2022-10-25 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥4,220,831,436.66, representing a 69.55% increase year-over-year[5]. - Net profit attributable to shareholders was ¥155,533,256.64, up 9.81% compared to the same period last year[5]. - Operating income for the year-to-date period was ¥10,352,346,770.49, showing a 55.93% increase year-over-year[5]. - Total operating revenue for the third quarter reached ¥10,352,346,770.49, a significant increase of 55.5% compared to ¥6,638,953,683.98 in the same period last year[19]. - Net profit for the period was ¥585,753,265.55, representing a year-over-year increase of 19.1% from ¥491,658,011.86[19]. - The company reported a comprehensive income total of ¥585,753,265.55, compared to ¥491,658,011.86 in the previous period, reflecting an increase of approximately 19.1%[20]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥12,015,658,193.51, reflecting a 21.26% increase from the previous year[5]. - The company's total assets increased to ¥12,015,658,193.51, up from ¥9,908,877,185.13, reflecting a growth of 21.4%[18]. - Current assets totaled ¥7,803,011,619.28, an increase of 25.1% compared to ¥6,239,508,079.38 at the beginning of the year[18]. - The total liabilities of the company reached ¥6,313,369,527.25, up from ¥4,722,189,876.28, reflecting a growth of 33.7%[18]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥412,493,346.75, down 2.77% compared to the previous year[5]. - The net cash flow from operating activities was ¥412,493,346.75, slightly down from ¥424,223,456.90 in the previous period, indicating a decrease of about 2.0%[22]. - Cash and cash equivalents at the end of the period totaled ¥1,322,555,176.00, up from ¥915,512,081.13, representing an increase of approximately 44.4%[22]. - The net increase in cash and cash equivalents was ¥462,666,321.56, compared to ¥387,153,479.37 in the previous period, showing an increase of about 19.5%[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,147[11]. - The largest shareholder, Wang Aiguo, holds 46.45% of the shares, amounting to 126 million shares, with 62,963,999 shares pledged[11]. - Qingdao Century Star Investment Co., Ltd. holds 6.64% of the shares, equivalent to 18 million shares[11]. - The top ten shareholders include various institutional and individual investors, with significant stakes held by domestic natural persons[11]. - The company has not disclosed any related party transactions among the top shareholders[12]. Investment and Expenses - The company experienced a 300.83% increase in investment properties due to the transfer of land use rights from a subsidiary[9]. - Research and development expenses increased by 30.54% year-over-year, attributed to higher R&D investments and personnel growth[9]. - The company reported a significant rise in research and development expenses, totaling ¥248,599,836.91, compared to ¥190,433,020.13 in the previous year, marking a 30.5% increase[19]. - The company’s sales expenses rose by 50.37% year-over-year, driven by business expansion and increased product sales[9]. - Government subsidies recognized in the current period amounted to ¥13,409,262.39, contributing to a 123.74% increase in other income compared to the previous year[9]. Financing Activities - The company raised ¥2,041,800,000.00 from financing activities, compared to ¥1,442,867,710.00 in the previous period, indicating an increase of about 41.5%[22]. - The company paid ¥1,183,703,680.59 in debt repayments, which is an increase from ¥662,100,000.00 in the previous period, reflecting a rise of approximately 78.5%[22]. Business Operations - The report indicates that the company is actively engaging in market expansion and investment strategies[16]. - The employee stock ownership plan for the subsidiary Dongbao Biotechnology was approved and implemented in July 2022[15]. - The company increased its stake in Qingdao Yiqing Biotechnology Co., Ltd. from 32% to 33.36% after a capital increase of 40.18 million RMB[13]. - The total capital increase amount for the investment in Qingdao Yiqing is 100.45 million RMB, with the company contributing 40.18 million RMB[13]. - The company has completed the business registration changes for Qingdao Yiqing and received the business license[14]. Audit Information - The company did not undergo an audit for the third quarter report[23].